ALTO-101 is under clinical development by Alto Neuroscience and currently in Phase II for Cognitive Impairment Associated With Schizophrenia (CIAS). According to GlobalData, Phase II drugs for Cognitive Impairment Associated With Schizophrenia (CIAS) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ALTO-101 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALTO-101 overview
ALTO-101 is under development for the treatment of cognitive impairment associated with schizophrenia. The drug candidate acts by targeting phosphodiesterase 4 (PDE4). It is administered by transdermal route.
It was also under development for the treatment of unspecified neurologic disorders
Alto Neuroscience overview
Alto Neuroscience is a biopharmaceutical company that develops drugs for psychiatric and mental health conditions. It is investigating ALTO-100, ALTO-202, and ALTO-300 drugs for the treatment of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) by targeting cognition, emotion, and sleep systems. The company utilizes its AI-enabled drug development platform that identifies biomarkers by evaluating brain function measures to develop its product candidates. It serves throughout the US. Alto Neuroscience is headquartered in Los Altos, California, the US.
For a complete picture of ALTO-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
